Advertisement
 

doctorslounge.com

 
Powered by
Careerbuilder

 

                    Home  |  Forums  |  Humor  |  Advertising  |  Contact
   Ask a Doctor

   News via RSS

   Newsletter

   Oncology

   News

 

 Conferences


   CME

   Forum Archives

   Diseases

   Symptoms

   Labs

   Procedures

   Drugs

   Links
   Specialties

   Cardiology

   Dermatology

   Endocrinology

   Fertility

   Gastroenterology

   Gynecology

   Hematology

   Infections

   Nephrology

   Neurology

   Oncology

   Orthopedics

   Pediatrics

   Pharmacy

   Primary Care

   Psychiatry

   Pulmonology

   Rheumatology

   Surgery

   Urology

   Other Sections

   Membership

   Research Tools

   Medical Tutorials

   Medical Software

 

 Headlines:

 
 

Back to index

Cisplatin - cyclophosphamide regimen

Abstract: Cyclophosphamide plus cis-platinum in combination: treatment program for stage III or IV ovarian carcinoma.

A randomized prospective comparison of treatment with cyclophosphamide and that with cyclophosphamide and cisplatinum, each in 21 patients with advanced ovarian cancer, has shown that the time to progression of tumor and the duration of survival were markedly improved in the patients receiving the combination chemotherapy. Cytoreductive surgery was performed in most of the patients in the study before the chemotherapy regimen was initiated. Second-look surgery was performed after a year of chemotherapy. The chemotherapy was administered on an outpatient basis, without excessive toxicity. At 2 years, 52.4% of the patients receiving combination therapy had no progression of tumor, whereas 9.5% had no progression of tumor in the group of patients receiving a single alkylating agent. Survival at 2 years was 61.9% for the combination chemotherapy group and 19.0% for those treated with cyclophosphamide alone. The study demonstrates a striking superiority of combination chemotherapy over single-agent chemotherapy in patients with advanced ovarian cancer.

References

Decker DG, Fleming TR, Malkasian GD Jr, Webb MJ, Jeffries JA, Edmonson JH. Cyclophosphamide plus cis-platinum in combination: treatment program for stage III or IV ovarian carcinoma. Obstet Gynecol. 1982 Oct;60(4):481-7.

advertisement.gif (61x7 -- 0 bytes)
 

Are you a doctor or a nurse?

Do you want to join the Doctors Lounge online medical community?

Participate in editorial activities (publish, peer review, edit) and give a helping hand to the largest online community of patients.

Click on the link below to see the requirements:

Doctors Lounge Membership Application


Regimen

Original regimen as described by Decker:

Cyclophosphamide....... 1000 mg / M2 IV day 1
Cisplatin....... 50 mg / M2 IV day 1
FREQUENCY 21 days

Decker DG et al. Obstet Gynecol. 1982 Oct;60(4):481-7.

More recent regimens:

Cyclophosphamide....... 600 mg / M2 IV day 1
Cisplatin....... 100 mg / M2 IV day 1
FREQUENCY 21 days

Alberts et al. J Clin Oncol 1992; 10:706 - 717.

Cyclophosphamide....... 750 mg / M2 IV day 1
Cisplatin....... 75 mg / M2 IV day 1
FREQUENCY every 21 days

McGuire et al. NEJM 1996; 334:1 - 6.


     
  Summary Cisplatin - cyclophosphamide vs. cyclophosphamide in stage III & IV ovarian cancer.
  Progression Free Survival @ 2 years 52.4% v. 9.5%
  Overall Survival @ 2 years 61.9% v. 19.0%.
     

Article reviewed by:

Dr. Tamer Fouad, M.D.

 

 advertisement.gif (61x7 -- 0 bytes)

 

 



We subscribe to the HONcode principles of the HON Foundation. Click to verify.
We subscribe to the HONcode principles. Verify here

Privacy Statement | Terms & Conditions | Editorial Board | About us
Copyright 2001-2012 DoctorsLounge. All rights reserved.